Dopamine D3 receptor ligands: recent advances in the control of subtype selectivity and intrinsic activity.

Various pharmacological studies have implicated the dopamine D(3) receptor as an interesting therapeutic target in the treatment of different neurological disorders. Because of these putative therapeutic applications, D(3) receptor ligands with diverse intrinsic activities have been an active field of research in recent years. Separation of purely D(3)-mediated drug effects from effects produced by interactions with similar biogenic amine receptors allows to verify the therapeutic impact of D(3) receptors and to reduce possible side-effects caused by "promiscuous" receptor interactions. The requirement to gain control of receptor selectivity and in particular subtype selectivity has been a challenging task in rational drug discovery for quite a few years. In this review, recently developed structural classes of D(3) ligands are discussed, which cover a broad spectrum of intrinsic activities and show interesting selectivities.

[1]  Harald Hübner,et al.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.

[2]  P. Sokoloff,et al.  Development of Novel 1,2,3,4‐Tetrahydroisoquinoline Derivatives and Closely Related Compounds as Potent and Selective Dopamine D3 Receptor Ligands , 2004, Chembiochem : a European journal of chemical biology.

[3]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[4]  F. Boeckler,et al.  Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists. , 2005, Journal of medicinal chemistry.

[5]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[6]  Harald Hübner,et al.  Analogues of FAUC 73 revealing new insights into the structural requirements of nonaromatic dopamine D3 receptor agonists. , 2004, Bioorganic & medicinal chemistry.

[7]  J. Palacios,et al.  High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review. , 2012, Analytica chimica acta.

[8]  B. Ferger,et al.  Neurochemical findings in the MPTP model of Parkinson's disease , 2001, Journal of neural transmission.

[9]  B. Gulyás,et al.  Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [ 11 C ]RGH-1756 in the monkey brain , 2004, Neurochemistry International.

[10]  P. Gmeiner,et al.  Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. , 2000, Journal of medicinal chemistry.

[11]  P. Gmeiner,et al.  Dopaminergic 7-aminotetrahydroindolizines: ex-chiral pool synthesis and preferential D3 receptor binding. , 2001, Bioorganic & medicinal chemistry letters.

[12]  P. Gmeiner,et al.  Parallel synthesis and biological screening of dopamine receptor ligands taking advantage of a click chemistry based BAL linker. , 2005, Journal of combinatorial chemistry.

[13]  B. Everitt,et al.  Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist , 1999, Nature.

[14]  Peter Gmeiner,et al.  Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes. , 2005, Journal of medicinal chemistry.

[15]  Harald Hübner,et al.  Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist. , 2005, Bioorganic & medicinal chemistry.

[16]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[17]  B. Kiss,et al.  Substituted phenoxyalkylpiperazines as dopamine D3 receptor ligands. , 2001, Die Pharmazie.

[18]  C. Humblet,et al.  G-Protein coupled receptors: models, mutagenesis, and drug design. , 1998, Journal of medicinal chemistry.

[19]  R. Mach,et al.  Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands , 2004 .

[20]  Robert H Mach,et al.  Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.

[21]  F. Corpet.  Multiple sequence alignment with hierarchical clustering. , 1988, Nucleic acids research.

[22]  P. Sokoloff,et al.  A functional test identifies dopamine agonists selective for D3 versus D2 receptors. , 1995, Neuroreport.

[23]  Jonathan A Javitch,et al.  The Ants Go Marching Two by Two: Oligomeric Structure of G-Protein-Coupled Receptors , 2004, Molecular Pharmacology.

[24]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[25]  G. Aston-Jones,et al.  Behavioural pharmacology: Breaking the chain of addiction , 1999, Nature.

[26]  Mark Froimowitz,et al.  Homology modeling of the dopamine D2 receptor and its testing by docking of agonists and tricyclic antagonists. , 1994, Journal of medicinal chemistry.

[27]  J. Yuan,et al.  NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. , 1998, Bioorganic & medicinal chemistry letters.

[28]  M. Reiser,et al.  Loss of response to levodopa in Parkinson’s disease and co-occurrence with dementia: role of D3 and not D2 receptors , 2002, Brain Research.

[29]  B. Gulyás,et al.  Radiochemical labelling of the dopamine D3 receptor ligand RGH‐1756 , 2000 .

[30]  Vincenzo Tortorella,et al.  Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands. , 2002, Journal of medicinal chemistry.

[31]  Torsten Kuwert,et al.  Synthesis and radioiodination of selective ligands for the dopamine D3 receptor subtype. , 2004, Bioorganic & medicinal chemistry letters.

[32]  G. Riley,et al.  Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. , 2000, European journal of pharmacology.

[33]  G. Gonnet,et al.  Exhaustive matching of the entire protein sequence database. , 1992, Science.

[34]  P. Sokoloff,et al.  N-(ω-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor Ligands , 2003 .

[35]  J. Feldon,et al.  Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice. , 2003, Biochemical pharmacology.

[36]  M. Millan,et al.  Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.

[37]  G. Schneider,et al.  From Virtual to Real Screening for D3 Dopamine Receptor Ligands , 2005, Chembiochem : a European journal of chemical biology.

[38]  A. Newman,et al.  N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[39]  D. Sibley,et al.  D3 Dopamine Receptor , 2007 .

[40]  I. Laszlovszky,et al.  Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats , 2005, Psychopharmacology.

[41]  Thomas Boraud,et al.  Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function , 2003, Nature Medicine.

[42]  N. Sheppard.  Hydrogen Bonding , 1971, Nature.

[43]  C. Chidester,et al.  Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands. , 1993, Journal of medicinal chemistry.

[44]  E. Novellino,et al.  Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. , 2003, Journal of medicinal chemistry.

[45]  Frank Böckler.  Rezeptor-vermittelte Parkinson-Therapeutika. Konkurrenz für den “Goldstandard” L-DOPA? , 2006 .

[46]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[47]  Shaomeng Wang,et al.  Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands. , 2005, Bioorganic & medicinal chemistry letters.

[48]  Harald Hübner,et al.  Practical ex-chiral-pool methodology for the synthesis of dopaminergic tetrahydroindoles , 2004 .

[49]  J. Ballesteros,et al.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.

[50]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[51]  M. E. Lajiness,et al.  Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. , 1995, European journal of pharmacology.

[52]  F. Boeckler,et al.  Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles. , 2005, Journal of medicinal chemistry.

[53]  Francesco Berardi,et al.  Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors. , 2006, Journal of medicinal chemistry.

[54]  J. Rubin,et al.  Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligands , 1997 .

[55]  P. Gmeiner,et al.  Synthesis and evaluation of 18F-labeled dopamine D3 receptor ligands as potential PET imaging agents. , 2005, Bioorganic & medicinal chemistry letters.

[56]  A. Davis,et al.  Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis , 1999 .

[57]  P. Sokoloff,et al.  Identification of the dopamine autoreceptor in the guinea‐pig retina as D2 receptor using novel subtype‐selective antagonists , 2001, British journal of pharmacology.

[58]  Peter Gmeiner,et al.  Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus , 2006, Synapse.

[59]  J. Schwartz,et al.  Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}carboxamides. , 2005, Bioorganic & Medicinal Chemistry.

[60]  F. Boeckler,et al.  Fancy bioisosteres: synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.

[61]  K. Wicke,et al.  The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. , 2001, European journal of pharmacology.

[62]  S. Strakowski,et al.  D3 dopamine receptor, behavioral sensitization, and psychosis , 2001, Neuroscience & Biobehavioral Reviews.

[63]  A. Newman,et al.  Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype. , 2001, Journal of medicinal chemistry.

[64]  F. Fazio,et al.  11C-labeling of n-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide derivatives and evaluation as potential radioligands for PET imaging of dopamine D3 receptors. , 2005, Journal of medicinal chemistry.

[65]  P. Sokoloff,et al.  Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. , 1999, European journal of pharmacology.

[66]  R. Mach,et al.  Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. , 2004, Bioorganic & medicinal chemistry letters.

[67]  M. Martres,et al.  Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. , 1994, European journal of pharmacology.

[68]  P. Sokoloff,et al.  Role of dopamine D3 receptors in thermoregulation: a reappraisal , 2000, Neuroreport.

[69]  Erin E. Carlson,et al.  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. , 2005, Journal of medicinal chemistry.

[70]  J. Joyce,et al.  Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.